Arcutis Biotherapeutics Inc logo


Arcutis Biotherapeutics Inc


Earnings Summary

Net Profits


Net Profits:

Arcutis Biotherapeutics Inc’s net profit fell -60.46% since last year same period to $-67.41Mn in the Q2 2022. On a quarterly growth basis, Arcutis Biotherapeutics Inc has generated -4.79% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Arcutis Biotherapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

Arcutis Biotherapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.41 - a 6% jump from last quarter’s estimates.

EPS Estimate Current Year:

Arcutis Biotherapeutics Inc’s earning per share (EPS) estimates for the current year stand at -1.41.

Key Ratios

Key ratios of the Arcutis Biotherapeutics Inc post its Q2 2022 earnings

Return on Assets (ROA)
Return on Equity (ROE)
Dividend Per Share (DPS)


Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Arcutis Biotherapeutics Inc’s return on assets (ROA) stands at -0.44.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Arcutis Biotherapeutics Inc’s return on equity (ROE) stands at -0.85.

Dividend Per Share (DPS):

Arcutis Biotherapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis' robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company's lead product candidate, topical roflumilast, has the potential to become the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.

Arcutis Biotherapeutics Inc
Health Technology